Cytotoxic T Lymphocyte Therapy (CTL Therapy)
Therapy involving the in vitro proliferation of antigen-specific cytotoxic T lymphocytes and reintroduction of cells into the patient’s body
Adoptive cellular immunotherapy using HCMV- or EBV-specific cytotoxic T lymphocytes after hematopoietic stem cell transplantation (HSCT) to prevent reactivation or infection of human cytomegalovirus (HCMV) and Epstein-Barr virus (EBV) is very effective in recovering cellular immunity.
Characteristics of CTL therapy
The traditional induction and proliferation of cytotoxic T lymphocytes (CTL) requires the use of separate antigen-presenting cells such as B cells transformed by EBV or dendritic cells or recombinant viruses to impart antigen specificity, which is restricted to histocompatibility antigen (HLA), requires high costs, and has long-term culture periods. To resolve these problems, Pharos Vaccine has used recombinant overlapping peptides, which has been mainly used for exploring the immunodominant epitope of immune cells, as an antigen to develop an innovative CTL in vitro culture and proliferation methods.
The CTL therapy of Pharos Vaccine involves the efficient proliferation of virus-specific T cells in the peripheral blood using viral antigen peptides, IL-2, and anti-CD3 antibodies and injection into the patient’s body to prevent and treat infectious diseases after hematopoietic stem cell transplantation.
Also, to prevent reactivation of virus and disease progression in patients with chronic hepatitis B or hepatitis B-derived hepatic cancer, we are developing CTL therapeutics using dendritic cells to culture HBV-specific T cells and injecting them into the patient’s body.
Isolation & Activation